Allergy Therapeutics (LON:AGY) Sets New 12-Month Low – Time to Sell?

Allergy Therapeutics plc (LON:AGY)’s share price reached a new 52-week low on Monday . The stock traded as low as GBX 6.50 and last traded at GBX 7, with a volume of 68370 shares. The stock had previously closed at GBX 7.

Allergy Therapeutics Stock Performance

The company has a market capitalization of £398.95 million, a P/E ratio of -6.49, a PEG ratio of -30.70 and a beta of 0.85. The stock’s fifty day moving average price is GBX 9.07 and its 200-day moving average price is GBX 10.34. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. The business had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. As a group, research analysts anticipate that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.